{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:09:53Z","timestamp":1791684593104,"version":"4.3.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371411"],"award-info":[{"award-number":["82371411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to evaluate the therapeutic efficacy of telitacicept based on the conventional treatment in adults with idiopathic inflammatory myopathy (IIM), focusing on its impact on clinical manifestations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>IIM patients who had been treated with telitacicept for at least 3\u2009months based on the conventional treatment from January 2023 to January 2024 were included in this study. The clinical response to telitacicept was determined based on the ACR\/EULAR criteria for minimal, moderate and major improvement in the Total Improvement Score. Disease activity was monitored using core set measures, while myositis damage was assessed with established assessment tools. The Manual Muscle Test for eight muscle groups (MMT-8) was used to assess the muscle performance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 11 patients administered with telitacicept (160\u2009mg per week) were included in this study. Post-treatment assessments revealed improvements in all patients according to ACR\/EULAR criteria. Notably, there was a significant reduction in the prednisone dosage from baseline to last visit [27.05\u2009(12.47) to 12.05\u2009(7.32)\u2009mg; P\u2009&amp;lt;\u20090.005]. An enhancement was observed in the MMT-8 score [which improved from 109.18\u2009(14.18) to 137.64\u2009(15.28); P\u2009&amp;lt;\u20090.005], and there was a reduction in creatine kinase level [from 2670.27\u2009(2675.00) to 561.09\u2009(754.09)\u2009U\/l; P\u2009&amp;lt;\u20090.05].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Telitacicept demonstrated effectiveness in treating refractory inflammatory myopathy, contributing to a significant reduction in steroid dosage among the patients. These findings highlight the potential of telitacicept as a valuable therapeutic option in the management of IIM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae601","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T15:04:03Z","timestamp":1730732643000},"page":"2945-2952","source":"Crossref","is-referenced-by-count":7,"title":["Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study"],"prefix":"10.1093","volume":"64","author":[{"given":"Huajie","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1022","authenticated-orcid":false,"given":"Mengge","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengcui","family":"Gui","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqiong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"2025050316130850300_keae601-B1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025050316130850300_keae601-B2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"New Engl J Med"},{"key":"2025050316130850300_keae601-B3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"New Engl J Med"},{"key":"2025050316130850300_keae601-B4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscular Disord NMD"},{"key":"2025050316130850300_keae601-B5","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"2025050316130850300_keae601-B6","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis and rheumatism"},{"key":"2025050316130850300_keae601-B7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025050316130850300_keae601-B8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025050316130850300_keae601-B9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Annals of the rheumatic diseases"},{"key":"2025050316130850300_keae601-B10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc2214285","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"388","author":"Werth","year":"2023","journal-title":"New Engl J Med"},{"key":"2025050316130850300_keae601-B11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11926-023-01105-w","article-title":"Intravenous immunoglobulin in idiopathic inflammatory myopathies: a practical guide for clinical use","volume":"25","author":"Gandiga","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"2025050316130850300_keae601-B12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/s10165-012-0627-8","article-title":"Accumulation of mature B cells in the inflamed muscle tissue of a patient with anti-155\/140 antibody-positive juvenile dermatomyositis","volume":"23","author":"Yokoyama","year":"2013","journal-title":"Modern Rheumatol"},{"key":"2025050316130850300_keae601-B13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00401-009-0570-8","article-title":"Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities?","volume":"118","author":"Brunn","year":"2009","journal-title":"Acta Neuropathol"},{"key":"2025050316130850300_keae601-B14","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","article-title":"Plasma cells in muscle in inclusion body myositis and polymyositis","volume":"65","author":"Greenberg","year":"2005","journal-title":"Neurology"},{"key":"2025050316130850300_keae601-B15","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/mus.21739","article-title":"Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles","volume":"42","author":"Salajegheh","year":"2010","journal-title":"Muscle Nerve"},{"key":"2025050316130850300_keae601-B16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4049\/jimmunol.178.1.547","article-title":"A local antigen-driven humoral response is present in the inflammatory myopathies","volume":"178","author":"Bradshaw","year":"2007","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"2025050316130850300_keae601-B17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"2025050316130850300_keae601-B18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025050316130850300_keae601-B19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13075-014-0454-8","article-title":"Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52\/anti-Ro60 autoantibodies","volume":"16","author":"Kry\u0161t\u016ffkov\u00e1","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025050316130850300_keae601-B20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","article-title":"Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis","volume":"20","author":"Kry\u0161t\u016ffkov\u00e1","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025050316130850300_keae601-B21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jneuroim.2012.04.006","article-title":"The expression of BAFF in the muscles of patients with dermatomyositis","volume":"249","author":"Baek","year":"2012","journal-title":"J Neuroimmunol"},{"key":"2025050316130850300_keae601-B22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2024","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025050316130850300_keae601-B23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025050316130850300_keae601-B24","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Invited article: inhibition of B cell functions: implications for neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"key":"2025050316130850300_keae601-B25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.coi.2021.06.014","article-title":"BAFF signaling in health and disease","volume":"71","author":"Schweighoffer","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2025050316130850300_keae601-B26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","article-title":"Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells","volume":"71","author":"Cornelis","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2025050316130850300_keae601-B27","doi-asserted-by":"crossref","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"2025050316130850300_keae601-B28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrrheum.2010.2","article-title":"Immunotherapy of myositis: issues, concerns and future prospects","volume":"6","author":"Dalakas","year":"2010","journal-title":"Nature reviews Rheumatology"},{"key":"2025050316130850300_keae601-B29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","article-title":"Therapy of polymyositis and dermatomyositis","volume":"11","author":"Marie","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2025050316130850300_keae601-B30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025050316130850300_keae601-B31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025050316130850300_keae601-B32","doi-asserted-by":"crossref","first-page":"1019972","DOI":"10.3389\/fimmu.2022.1019972","article-title":"Anti-SRP immune-mediated necrotizing myopathy: a critical review of current concepts","volume":"13","author":"Ma","year":"2022","journal-title":"Front Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae601\/60750524\/keae601.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2945\/60750524\/keae601.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2945\/60750524\/keae601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:13:27Z","timestamp":1746303207000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2945\/7874972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,11,4]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae601","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,11,4]]}}}